Many heart patients get newer, pricey stents inserted during artery-clearing procedures, even if it s not clear they d be worse off with more basic models, a new study suggests.
Cardionovum GmbH announced today that it has initiated in vivo testing of its second drug-eluting balloon (DEB) RESTORE™. The Company is currently marketing a line of CE-marked paclitaxel-coated DEBs for (1) coronary (PRIMUS®) and (2) peripheral (LEGFLOW®) applications. Cardionovum is featured in the most recent issue of IN VIVO magazine.
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today announced that two patients at two different hospitals were treated with its new, 6 French guide catheter-compatible, electric orbital atherectomy system. The treatments are part of CSI s ORBIT II trial, which is now over 70 percent enrolled. ORBIT II is evaluating the safety and effectiveness of CSI’s orbital technology in treating calcified coronary arteries.
Boston Scientific Corporation (BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug Administration (FDA) approval for the WATCHMAN® Left Atrial Appendage (LAA) Closure device. The prospective, randomized trial enrolled 407 patients at 42 sites and is comparing the WATCHMAN device to warfarin in high-risk patients with atrial fibrillation (AF) eligible for long-term warfarin therapy. Patient follow up of six months is required prior to submission to the FDA.
Edwards Lifesciences Corporation (EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received a conditional Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate the TRANSFORM Trial, a prospective, multi-center study that will evaluate the EDWARDS INTUITY valve system.
Los pacientes con disfunción eréctil tienen una alta probabilidad de padecer un infarto de miocardio en el plazo de tres años. En el mes de la esterilidad, el hospital madrileño inaugura la nueva Unidad de Andrología y Salud Sexual.
Depressive symptoms appear to be involved in the relationship between health-related quality of life and cardiac event-free survival in patients with heart failure, researchers found. Both depressive symptoms and health-related quality of life were independently associated with cardiac event-free survival among patients treated in heart failure clinics, according to Kyoung Suk Lee, PhD, RN, of the University of Kentucky in Lexington.
Habitual drinkers of a moderate amount of coffee may lower their risk of heart failure, a meta-analysis of Swedish and Finnish studies showed. The largest relative risk reduction (11%) was associated with four to five European servings per day, which is the equivalent of about two cups of coffee at popular chains in the U.S., according to Murray Mittleman, MD, DrPH, of Beth Israel Deaconess Medical Center in Boston, and colleagues.
On 18 June 2012, Edwards Lifesciences announced that it has received the CE mark in Europe for the Ascendra+ system for the delivery of the Edwards Sapien XT transcatheter heart valve. It is the first delivery system optimised for both transapical and transaortic implantation of a transcatheter heart valve.
AstraZeneca announced last week that full data results of the PLATO health economics substudy, which have been published online in the European Heart Journal, demonstrate that even at a higher drug cost and incremental cost per acute coronary syndromes (ACS) patient, ticagrelor (known as BRILIQUE in the European Union and BRILINTA elsewhere) numerically lowered non-drug healthcare costs versus generic clopidogrel and is cost-effective.
Young, healthy adults exposed to ozone - a component of air pollution - for 2 hours had changes in markers of inflammation, thrombosis, and heart rate variability, a randomized crossover study found. They showed an 85.3% increase (95% CI 44.1 to 138.5) in blood levels of the inflammatory chemokine interleukin (IL)-8, according to Robert B. Devlin, PhD, of the U.S. Environmental Protection Agency, and colleagues.
La angioplastia primaria para el tratamiento del infarto ha crecido un 16% respecto al último año. XXIII Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista de la SEC.
On October 11-12, 2012, the Duke Clinical Research Institute, in conjunction with the Society for Cardiovascular Angiography and Interventions (SCAI), will present the "2nd Annual Duke Masters Course in Transradial Intervention", continuing its commitment to providing an advanced level of training in this new and growing technique to be offered in the United States. According to the organizers, the Duke course is one of the only advanced Masters level transradial courses offered in the U.S.
Drug-eluting stents (DESs) do not seem to offer advantages over bare-metal stents (BMSs) for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stent implantation, according to research published in the July 1 issue of The American Journal of Cardiology.
New clinical data published in the International Journal of Cardiologysupports that OrbusNeich s Genous Stent is safe and effective in patients who discontinue DAPT within 15 days of stent placement. Specifically, no differences in rates of stent thrombosis (ST) and other clinical outcomes were observed between patients who discontinued DAPT prior to and after 15 days, according to the results of ARGENTO, a consecutive, prospective study in 384 patients undergoing single or multivessel percutaneous coronary intervention (PCI) with the Genous Stent
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos